• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Psychedelic Mushrooms May Help Treatment Resistant Depression
RESEARCH UPDATE

Psychedelic Mushrooms May Help Treatment Resistant Depression

June 1, 2016
Bret A. Moore, PsyD, ABPP
From The Carlat Addiction Treatment Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Bret A. Moore, PsyD, ABPP

Board-Certified Clinical Psychologist, San Antonio, TX

Dr. Moore has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Subject:
(Carhart-Harris RL et al, Lancet Psychiatry, 2016; Epub ahead of print)

Short Description:

Mushrooms have been used as medicine for thousands of years, but it wasn’t until the 1950s that scientists took note of their potential healing properties. Psilocybin, a naturally occurring and psychedelic compound of the Psilocybe species of mushrooms, has garnered the most attention. 

Psilocybin is essentially a serotonin 2A agonist. Theoretically, this action should mediate depressive symptoms, but we don’t know for sure because no available antidepressants are direct agonists of this receptor. Researchers from the United Kingdom set out to see if this is indeed the case.

As part of an open-label feasibility study, six men and six women with moderate to severe treatment resistant depression (defined as two failed antidepressant trials) were administered a 10 mg oral dose of psilocybin and another 25 mg dose one week later. The goal of the first, lower dose was to test safety and tolerability; the second dose was the actual treatment. Researchers then monitored depressive symptoms with the Quick Inventory of Depressive Symptoms (QIDS) 1 week and 3 months post-treatment.

Overall, patients tolerated the psychedelic experience well. Short-term confusion or unclear thinking (n=9), nausea (n=4), and headaches (n=4) were the most common adverse effects. However, all patients experienced transient and mild to moderate anxiety shortly after taking the drug. It’s important to note that no patients dropped out of treatment because of side effects or the intensity associated with taking a psychedelic drug. Compared to baseline, scores were 11.8 and 9.2 points lower on the QIDS at 1 week and 3 months post-treatment, respectively.

TCPR’s Take: Exploring novel methods for battling treatment resistant depression is important since many patients don’t respond to antidepressants or psychotherapy. Ketamine (see TCPR, June 2016) and ultra-low dose buprenorphine (see TCPR, July/August 2016) are perfect examples. Both are “outside the box” treatments for severe depression and show tremendous promise. Psilocybin, a naturally occurring chemical found in certain psychedelic mushrooms, may have just joined their ranks. Although this is a very small, uncontrolled study, the initial results are promising and open the door for a more definitive, randomized clinical trial. 


                                                                                        


Addiction Treatment Research Update
KEYWORDS depressive_disorder research_updates
    Bret a moore psyd abpp
    Bret A. Moore, PsyD, ABPP

    Good News for Smoking Cessation Drugs: Not as Scary as Once Thought

    More from this author
    www.thecarlatreport.com
    Issue Date: June 1, 2016
    SUBSCRIBE NOW
    Table Of Contents
    Motivational Interviewing: Ten Tips
    Using Motivational Interviewing in Your Practice
    Psychedelic Mushrooms May Help Treatment Resistant Depression
    Good News for Smoking Cessation Drugs: Not as Scary as Once Thought
    DOWNLOAD NOW
    Featured Book
    • OUDFB1e_Cover_Binding.png

      Treating Opioid Use Disorder—A Fact Book (2024)

      All the tools you need to assess and treat patients struggling with opioid use disorder. 
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2622607431.jpg
      General Psychiatry

      Should You Test MTHFR?

      MTHFR is a...
      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.